Sunshine Biopharma, Inc. (NASDAQ: SBFMW) Stock Competitors & Peer Comparison
See SBFMW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SBFMW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SBFMW | $0.03 | +0.00% | 4.2M | N/A | -$11.30 | N/A |
| TAK | $21.09 | +0.33% | 66.6B | 15.16 | $1.39 | +3.34% |
| TEVA | $42.97 | +0.84% | 50.1B | 14.67 | $2.93 | N/A |
| HLN | $8.97 | -1.86% | 39.4B | 18.35 | $0.49 | +2.21% |
| ZTS | $82.32 | +3.68% | 34B | 12.51 | $6.58 | +2.58% |
| VTRS | $20.49 | +2.91% | 23.5B | 8.13 | $2.52 | +2.34% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $26.84 | +4.27% | 13.4B | 25.33 | $1.06 | N/A |
| RDY | $15.05 | +0.97% | 12.5B | 32.02 | $0.47 | +0.55% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
SBFMW vs TAK Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TAK has a market cap of 66.6B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TAK trades at $21.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TAK's P/E ratio is 15.16. In terms of profitability, SBFMW's ROE is -0.24%, compared to TAK's ROE of +0.05%. Regarding short-term risk, SBFMW is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
SBFMW vs TEVA Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TEVA has a market cap of 50.1B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TEVA trades at $42.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TEVA's P/E ratio is 14.67. In terms of profitability, SBFMW's ROE is -0.24%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, SBFMW is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TEVA's competition here
Haleon plc (NYSE: HLN)
SBFMW vs HLN Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, HLN has a market cap of 39.4B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while HLN trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas HLN's P/E ratio is 18.35. In terms of profitability, SBFMW's ROE is -0.24%, compared to HLN's ROE of +0.10%. Regarding short-term risk, SBFMW is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
SBFMW vs ZTS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ZTS has a market cap of 34B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ZTS trades at $82.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ZTS's P/E ratio is 12.51. In terms of profitability, SBFMW's ROE is -0.24%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, SBFMW is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
SBFMW vs VTRS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, VTRS has a market cap of 23.5B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while VTRS trades at $20.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas VTRS's P/E ratio is 8.13. In terms of profitability, SBFMW's ROE is -0.24%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, SBFMW is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
SBFMW vs ITCI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ITCI's P/E ratio is -180.64. In terms of profitability, SBFMW's ROE is -0.24%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, SBFMW is similarly volatile compared to ITCI. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
SBFMW vs ELAN Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ELAN has a market cap of 13.4B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ELAN trades at $26.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ELAN's P/E ratio is 25.33. In terms of profitability, SBFMW's ROE is -0.24%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, SBFMW is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
SBFMW vs RDY Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, RDY has a market cap of 12.5B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while RDY trades at $15.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas RDY's P/E ratio is 32.02. In terms of profitability, SBFMW's ROE is -0.24%, compared to RDY's ROE of +0.07%. Regarding short-term risk, SBFMW is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check RDY's competition here
Catalent, Inc. (NYSE: CTLT)
SBFMW vs CTLT Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CTLT's P/E ratio is -27.84. In terms of profitability, SBFMW's ROE is -0.24%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, SBFMW is less volatile compared to CTLT. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
SBFMW vs ALKS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ALKS trades at $46.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 48.59. In terms of profitability, SBFMW's ROE is -0.24%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, SBFMW is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
SBFMW vs AMRX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, AMRX has a market cap of 7.4B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while AMRX trades at $21.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas AMRX's P/E ratio is 23.64. In terms of profitability, SBFMW's ROE is -0.24%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, SBFMW is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
SBFMW vs LNTH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while LNTH trades at $101.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas LNTH's P/E ratio is 16.97. In terms of profitability, SBFMW's ROE is -0.24%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, SBFMW is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
SBFMW vs INDV Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while INDV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas INDV's P/E ratio is 9.94. In terms of profitability, SBFMW's ROE is -0.24%, compared to INDV's ROE of -3.53%. Regarding short-term risk, SBFMW is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check INDV's competition here
Bausch Health Companies Inc. (NYSE: BHC)
SBFMW vs BHC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while BHC trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas BHC's P/E ratio is 2.14. In terms of profitability, SBFMW's ROE is -0.24%, compared to BHC's ROE of +0.59%. Regarding short-term risk, SBFMW is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check BHC's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
SBFMW vs RGC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, RGC has a market cap of 2.8B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while RGC trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas RGC's P/E ratio is -556.00. In terms of profitability, SBFMW's ROE is -0.24%, compared to RGC's ROE of -1.61%. Regarding short-term risk, SBFMW is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check RGC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
SBFMW vs HCM Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while HCM trades at $15.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas HCM's P/E ratio is 148.07. In terms of profitability, SBFMW's ROE is -0.24%, compared to HCM's ROE of +0.01%. Regarding short-term risk, SBFMW is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check HCM's competition here
Perrigo Company plc (NYSE: PRGO)
SBFMW vs PRGO Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, PRGO has a market cap of 2.4B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while PRGO trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas PRGO's P/E ratio is 6.78. In terms of profitability, SBFMW's ROE is -0.24%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, SBFMW is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
SBFMW vs DCPH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas DCPH's P/E ratio is -11.58. In terms of profitability, SBFMW's ROE is -0.24%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, SBFMW is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check DCPH's competition here
Alvotech (NASDAQ: ALVOW)
SBFMW vs ALVOW Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ALVOW has a market cap of 2.1B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ALVOW trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ALVOW's P/E ratio is 33.51. In terms of profitability, SBFMW's ROE is -0.24%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, SBFMW is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ALVOW's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
SBFMW vs AVDL Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, SBFMW's ROE is -0.24%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, SBFMW is similarly volatile compared to AVDL. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
SBFMW vs EMBCV Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas EMBCV's P/E ratio is N/A. In terms of profitability, SBFMW's ROE is -0.24%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, SBFMW is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check EMBCV's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
SBFMW vs TRLV Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TRLV trades at $11.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TRLV's P/E ratio is -4.48. In terms of profitability, SBFMW's ROE is -0.24%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, SBFMW is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TRLV's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
SBFMW vs ETON Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ETON has a market cap of 1.8B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ETON trades at $64.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ETON's P/E ratio is 169.36. In terms of profitability, SBFMW's ROE is -0.24%, compared to ETON's ROE of +1.05%. Regarding short-term risk, SBFMW is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ETON's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
SBFMW vs DVAX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas DVAX's P/E ratio is -41.89. In terms of profitability, SBFMW's ROE is -0.24%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, SBFMW is similarly volatile compared to DVAX. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
SBFMW vs ALVO Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ALVO trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ALVO's P/E ratio is -7.93. In terms of profitability, SBFMW's ROE is -0.24%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, SBFMW is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ALVO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
SBFMW vs TARO Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TARO's P/E ratio is 30.05. In terms of profitability, SBFMW's ROE is -0.24%, compared to TARO's ROE of +0.03%. Regarding short-term risk, SBFMW is less volatile compared to TARO. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TARO's competition here
Supernus, Inc. (NASDAQ: SUPN)
SBFMW vs SUPN Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, SUPN has a market cap of 1.6B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while SUPN trades at $27.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas SUPN's P/E ratio is -36.49. In terms of profitability, SBFMW's ROE is -0.24%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, SBFMW is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check SUPN's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
SBFMW vs ANIP Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ANIP trades at $67.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ANIP's P/E ratio is 8.25. In terms of profitability, SBFMW's ROE is -0.24%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, SBFMW is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ANIP's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
SBFMW vs PCRX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while PCRX trades at $36.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas PCRX's P/E ratio is 14.02. In terms of profitability, SBFMW's ROE is -0.24%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, SBFMW is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check PCRX's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
SBFMW vs PAHC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while PAHC trades at $34.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas PAHC's P/E ratio is 11.83. In terms of profitability, SBFMW's ROE is -0.24%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, SBFMW is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
SBFMW vs CRON Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CRON trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CRON's P/E ratio is 18.14. In terms of profitability, SBFMW's ROE is -0.24%, compared to CRON's ROE of +0.05%. Regarding short-term risk, SBFMW is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
SBFMW vs AMPH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, AMPH has a market cap of 1.3B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while AMPH trades at $29.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas AMPH's P/E ratio is 10.03. In terms of profitability, SBFMW's ROE is -0.24%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, SBFMW is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
SBFMW vs HROW Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while HROW trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas HROW's P/E ratio is -27.75. In terms of profitability, SBFMW's ROE is -0.24%, compared to HROW's ROE of -1.04%. Regarding short-term risk, SBFMW is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
SBFMW vs PETQ Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas PETQ's P/E ratio is 83.73. In terms of profitability, SBFMW's ROE is -0.24%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, SBFMW is less volatile compared to PETQ. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
SBFMW vs COLL Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, COLL has a market cap of 805.4M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while COLL trades at $24.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas COLL's P/E ratio is 3.10. In terms of profitability, SBFMW's ROE is -0.24%, compared to COLL's ROE of +0.12%. Regarding short-term risk, SBFMW is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
SBFMW vs IRWD Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, IRWD has a market cap of 775M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while IRWD trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas IRWD's P/E ratio is 6.01. In terms of profitability, SBFMW's ROE is -0.24%, compared to IRWD's ROE of -0.81%. Regarding short-term risk, SBFMW is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
SBFMW vs EVO Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, EVO has a market cap of 618M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while EVO trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas EVO's P/E ratio is -2.46. In terms of profitability, SBFMW's ROE is -0.24%, compared to EVO's ROE of -0.26%. Regarding short-term risk, SBFMW is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
SBFMW vs BDSI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas BDSI's P/E ratio is 6.82. In terms of profitability, SBFMW's ROE is -0.24%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, SBFMW is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check BDSI's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
SBFMW vs TKNO Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TKNO has a market cap of 528.8M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TKNO trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TKNO's P/E ratio is -27.65. In terms of profitability, SBFMW's ROE is -0.24%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, SBFMW is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TKNO's competition here
Evolus, Inc. (NASDAQ: EOLS)
SBFMW vs EOLS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, EOLS has a market cap of 460.7M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while EOLS trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas EOLS's P/E ratio is -22.09. In terms of profitability, SBFMW's ROE is -0.24%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, SBFMW is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
SBFMW vs KMDA Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, KMDA has a market cap of 443.7M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while KMDA trades at $7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas KMDA's P/E ratio is 20.24. In terms of profitability, SBFMW's ROE is -0.24%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, SBFMW is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check KMDA's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
SBFMW vs AQST Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, AQST has a market cap of 441.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while AQST trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas AQST's P/E ratio is -5.41. In terms of profitability, SBFMW's ROE is -0.24%, compared to AQST's ROE of +2.55%. Regarding short-term risk, SBFMW is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check AQST's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
SBFMW vs ACB Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ACB has a market cap of 339.6M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ACB trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ACB's P/E ratio is -3.73. In terms of profitability, SBFMW's ROE is -0.24%, compared to ACB's ROE of -0.21%. Regarding short-term risk, SBFMW is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ACB's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
SBFMW vs TLRY Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TLRY has a market cap of 319.8M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TLRY trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TLRY's P/E ratio is -2.04. In terms of profitability, SBFMW's ROE is -0.24%, compared to TLRY's ROE of -0.10%. Regarding short-term risk, SBFMW is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
SBFMW vs EBS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, EBS has a market cap of 312.8M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while EBS trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas EBS's P/E ratio is 4.24. In terms of profitability, SBFMW's ROE is -0.24%, compared to EBS's ROE of -0.61%. Regarding short-term risk, SBFMW is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
SBFMW vs ALIM Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ALIM's P/E ratio is 5.28. In terms of profitability, SBFMW's ROE is -0.24%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, SBFMW is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
SBFMW vs LNDC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas LNDC's P/E ratio is -4.04. In terms of profitability, SBFMW's ROE is -0.24%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, SBFMW is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check LNDC's competition here
Canopy Growth Corporation (NASDAQ: CGC)
SBFMW vs CGC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CGC has a market cap of 263.5M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CGC trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CGC's P/E ratio is -1.39. In terms of profitability, SBFMW's ROE is -0.24%, compared to CGC's ROE of -0.37%. Regarding short-term risk, SBFMW is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check CGC's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
SBFMW vs LFCR Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, LFCR has a market cap of 241.8M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while LFCR trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas LFCR's P/E ratio is -5.02. In terms of profitability, SBFMW's ROE is -0.24%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, SBFMW is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check LFCR's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
SBFMW vs SIGA Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, SIGA has a market cap of 234.6M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while SIGA trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas SIGA's P/E ratio is 12.09. In terms of profitability, SBFMW's ROE is -0.24%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, SBFMW is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
SBFMW vs TYHT Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TYHT's P/E ratio is -1.61. In terms of profitability, SBFMW's ROE is -0.24%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, SBFMW is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TYHT's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
SBFMW vs REPH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas REPH's P/E ratio is -8.04. In terms of profitability, SBFMW's ROE is -0.24%, compared to REPH's ROE of -0.22%. Regarding short-term risk, SBFMW is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check REPH's competition here
Glass House Brands Inc (NYSE: GLAS)
SBFMW vs GLAS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, GLAS has a market cap of 167.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while GLAS trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas GLAS's P/E ratio is -3.40. In terms of profitability, SBFMW's ROE is -0.24%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, SBFMW is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check GLAS's competition here
Theratechnologies Inc. (NASDAQ: THTX)
SBFMW vs THTX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas THTX's P/E ratio is -28.83. In terms of profitability, SBFMW's ROE is -0.24%, compared to THTX's ROE of +0.36%. Regarding short-term risk, SBFMW is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
SBFMW vs ASRT Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ASRT's P/E ratio is -7.10. In terms of profitability, SBFMW's ROE is -0.24%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, SBFMW is less volatile compared to ASRT. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
SBFMW vs DERM Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, DERM has a market cap of 127.9M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while DERM trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas DERM's P/E ratio is -20.59. In terms of profitability, SBFMW's ROE is -0.24%, compared to DERM's ROE of -0.20%. Regarding short-term risk, SBFMW is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
SBFMW vs CRDL Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CRDL has a market cap of 126.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CRDL trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CRDL's P/E ratio is -4.16. In terms of profitability, SBFMW's ROE is -0.24%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, SBFMW is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
SBFMW vs OGI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, OGI has a market cap of 123.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while OGI trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas OGI's P/E ratio is 1.96. In terms of profitability, SBFMW's ROE is -0.24%, compared to OGI's ROE of +0.21%. Regarding short-term risk, SBFMW is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check OGI's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
SBFMW vs ORGO Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ORGO has a market cap of 116.7M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ORGO trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ORGO's P/E ratio is 30.23. In terms of profitability, SBFMW's ROE is -0.24%, compared to ORGO's ROE of -0.47%. Regarding short-term risk, SBFMW is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
SBFMW vs SCTL Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas SCTL's P/E ratio is -7.86. In terms of profitability, SBFMW's ROE is -0.24%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, SBFMW is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
SBFMW vs BGM Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, BGM has a market cap of 105.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while BGM trades at $8.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas BGM's P/E ratio is -1.73. In terms of profitability, SBFMW's ROE is -0.24%, compared to BGM's ROE of -0.05%. Regarding short-term risk, SBFMW is similarly volatile compared to BGM. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
SBFMW vs PROC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas PROC's P/E ratio is 1.53. In terms of profitability, SBFMW's ROE is -0.24%, compared to PROC's ROE of -2.22%. Regarding short-term risk, SBFMW is similarly volatile compared to PROC. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
SBFMW vs OPTN Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas OPTN's P/E ratio is -4.42. In terms of profitability, SBFMW's ROE is -0.24%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, SBFMW is similarly volatile compared to OPTN. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
SBFMW vs ZOM Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ZOM's P/E ratio is -1.62. In terms of profitability, SBFMW's ROE is -0.24%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, SBFMW is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
SBFMW vs GRVI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas GRVI's P/E ratio is 26.05. In terms of profitability, SBFMW's ROE is -0.24%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, SBFMW is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check GRVI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
SBFMW vs CPIX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CPIX has a market cap of 80.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CPIX trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CPIX's P/E ratio is -13.37. In terms of profitability, SBFMW's ROE is -0.24%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, SBFMW is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check CPIX's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
SBFMW vs ZYBT Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ZYBT has a market cap of 72.5M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ZYBT trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ZYBT's P/E ratio is -7.65. In terms of profitability, SBFMW's ROE is -0.24%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, SBFMW is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
SBFMW vs ZYNE Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, SBFMW's ROE is -0.24%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, SBFMW is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
SBFMW vs SSIC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas SSIC's P/E ratio is 11.93. In terms of profitability, SBFMW's ROE is -0.24%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, SBFMW is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
SBFMW vs VLNS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas VLNS's P/E ratio is -1.03. In terms of profitability, SBFMW's ROE is -0.24%, compared to VLNS's ROE of N/A. Regarding short-term risk, SBFMW is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
SBFMW vs DRRX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas DRRX's P/E ratio is -4.44. In terms of profitability, SBFMW's ROE is -0.24%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, SBFMW is similarly volatile compared to DRRX. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
SBFMW vs TLPH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TLPH trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TLPH's P/E ratio is -4.00. In terms of profitability, SBFMW's ROE is -0.24%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, SBFMW is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TLPH's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
SBFMW vs JUPW Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas JUPW's P/E ratio is -2.41. In terms of profitability, SBFMW's ROE is -0.24%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, SBFMW is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check JUPW's competition here
InterCure Ltd. (NASDAQ: INCR)
SBFMW vs INCR Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, INCR has a market cap of 42.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while INCR trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas INCR's P/E ratio is -3.74. In terms of profitability, SBFMW's ROE is -0.24%, compared to INCR's ROE of -0.09%. Regarding short-term risk, SBFMW is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check INCR's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
SBFMW vs QLI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas QLI's P/E ratio is -4.92. In terms of profitability, SBFMW's ROE is -0.24%, compared to QLI's ROE of -0.16%. Regarding short-term risk, SBFMW is similarly volatile compared to QLI. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
SBFMW vs HEXO Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas HEXO's P/E ratio is -0.26. In terms of profitability, SBFMW's ROE is -0.24%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, SBFMW is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
SBFMW vs RMTI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, RMTI has a market cap of 30.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while RMTI trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas RMTI's P/E ratio is -5.61. In terms of profitability, SBFMW's ROE is -0.24%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, SBFMW is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
SBFMW vs CPHI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CPHI has a market cap of 25.4M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CPHI trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CPHI's P/E ratio is -1.37. In terms of profitability, SBFMW's ROE is -0.24%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, SBFMW is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check CPHI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
SBFMW vs SHPH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, SHPH has a market cap of 24.7M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while SHPH trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas SHPH's P/E ratio is -0.24. In terms of profitability, SBFMW's ROE is -0.24%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, SBFMW is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
SBFMW vs CYTH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CYTH's P/E ratio is -0.80. In terms of profitability, SBFMW's ROE is -0.24%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, SBFMW is similarly volatile compared to CYTH. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
SBFMW vs AYTU Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, AYTU has a market cap of 19.7M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while AYTU trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas AYTU's P/E ratio is -1.53. In terms of profitability, SBFMW's ROE is -0.24%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, SBFMW is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
SBFMW vs TXMD Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, TXMD has a market cap of 19.6M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while TXMD trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas TXMD's P/E ratio is 86.09. In terms of profitability, SBFMW's ROE is -0.24%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, SBFMW is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check TXMD's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
SBFMW vs EVOK Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas EVOK's P/E ratio is -7.97. In terms of profitability, SBFMW's ROE is -0.24%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, SBFMW is similarly volatile compared to EVOK. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
SBFMW vs ACRX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ACRX's P/E ratio is -0.31. In terms of profitability, SBFMW's ROE is -0.24%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, SBFMW is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ACRX's competition here
Optimi Health Corp. (NASDAQ: OPTH)
SBFMW vs OPTH Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, OPTH has a market cap of 13.5M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while OPTH trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas OPTH's P/E ratio is -1.51. In terms of profitability, SBFMW's ROE is -0.24%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, SBFMW is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check OPTH's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
SBFMW vs AGRX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas AGRX's P/E ratio is -0.89. In terms of profitability, SBFMW's ROE is -0.24%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, SBFMW is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
SBFMW vs CABR Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, CABR has a market cap of 8.8M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while CABR trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas CABR's P/E ratio is -1.25. In terms of profitability, SBFMW's ROE is -0.24%, compared to CABR's ROE of -3.86%. Regarding short-term risk, SBFMW is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check CABR's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
SBFMW vs INM Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, INM has a market cap of 8.5M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while INM trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas INM's P/E ratio is -5.07. In terms of profitability, SBFMW's ROE is -0.24%, compared to INM's ROE of -2.64%. Regarding short-term risk, SBFMW is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check INM's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
SBFMW vs NLTX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas NLTX's P/E ratio is -0.28. In terms of profitability, SBFMW's ROE is -0.24%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, SBFMW is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
SBFMW vs LCI Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas LCI's P/E ratio is -0.04. In terms of profitability, SBFMW's ROE is -0.24%, compared to LCI's ROE of +1.66%. Regarding short-term risk, SBFMW is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
SBFMW vs ADMP Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ADMP's P/E ratio is -0.08. In terms of profitability, SBFMW's ROE is -0.24%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, SBFMW is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check ADMP's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
SBFMW vs SBFM Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while SBFM trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas SBFM's P/E ratio is -0.45. In terms of profitability, SBFMW's ROE is -0.24%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, SBFMW is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check SBFM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
SBFMW vs SNOA Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, SNOA has a market cap of 5.6M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while SNOA trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas SNOA's P/E ratio is -1.05. In terms of profitability, SBFMW's ROE is -0.24%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, SBFMW is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
SBFMW vs MNK Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas MNK's P/E ratio is -0.44. In terms of profitability, SBFMW's ROE is -0.24%, compared to MNK's ROE of -0.36%. Regarding short-term risk, SBFMW is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
SBFMW vs YCBD Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, YCBD has a market cap of 4.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while YCBD trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas YCBD's P/E ratio is -0.95. In terms of profitability, SBFMW's ROE is -0.24%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, SBFMW is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
SBFMW vs FLGC Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas FLGC's P/E ratio is -0.19. In terms of profitability, SBFMW's ROE is -0.24%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, SBFMW is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check FLGC's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
SBFMW vs GELS Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, GELS has a market cap of 4.1M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while GELS trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas GELS's P/E ratio is -1.00. In terms of profitability, SBFMW's ROE is -0.24%, compared to GELS's ROE of -0.36%. Regarding short-term risk, SBFMW is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check GELS's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
SBFMW vs PLXP Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas PLXP's P/E ratio is -0.22. In terms of profitability, SBFMW's ROE is -0.24%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, SBFMW is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for SBFMW.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
SBFMW vs ATNX Comparison November 2026
Sunshine Biopharma, Inc. (NASDAQ: SBFMW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SBFMW stands at 4.2M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, SBFMW is priced at $0.03 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SBFMW currently has a P/E ratio of N/A, whereas ATNX's P/E ratio is -0.02. In terms of profitability, SBFMW's ROE is -0.24%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, SBFMW is similarly volatile compared to ATNX. This indicates similar risk in terms of short-term price fluctuations for SBFMW.Check ATNX's competition here